The moves, which include consolidating some small offices into larger facilities with multiple functions, are part of ongoing restructuring after Merck's acquisition of Schering-Plough Corp. last November. That $41 billion deal made Merck the world's second-biggest drugmaker by revenue, with roughly $45 billion in annual sales.
FULL ARTICLE AT The Journal Gazette